Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | March 05, 2021 | March 09, 2021 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | Director | January 15, 2021 | January 20, 2021 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | Director | June 15, 2026 | June 18, 2026 |
| OnKure Therapeutics, Inc.OKUR · Entity 6550 | Director | August 07, 2026 | August 11, 2026 |
| SPRUCE BIOSCIENCES, INC.SPRB · Entity 6471 | Director · Executive Chairman | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOMARIN PHARMACEUTICAL INC
Report date March 05, 2021 · Filed March 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,840 |
Ending reported balance
After 2021-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-03-05 · Exercise / conversion · Acquired 5,000 · Balance 47,840 Row 2 · 2021-03-05 · Sale · Disposed 5,000 · Balance 42,840 |
| Stock Option (Right to buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $26.49 · Expires 2021-05-11 | Direct | 0 |
Reported balance
After 2021-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-05 · Exercise / conversion · Disposed 5,000 · Balance 0 F1: Reflects the number of options outstanding after the transactions from this specific stock option grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the number of options outstanding after the transactions from this specific stock option grant.
Mirati Therapeutics, Inc.
Report date January 15, 2021 · Filed January 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,731 |
Reported balance
After 2021-01-15 transaction · row 1
1 source rowRow 1 · 2021-01-15 · Grant · Acquired 1,475 · Balance 5,731 F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. |
| Non Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $214.47 · Expires 2031-01-14 | Direct | 2,155 |
Reported balance
After 2021-01-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-15 · Grant · Acquired 2,155 · Balance 2,155 F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date.
F2: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant.
Mirum Pharmaceuticals, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $101.00 · Expires 2036-06-14 | Direct | 3,772 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 3,772 · Balance 3,772 F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,980 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 1,980 · Balance 1,980 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the grant date, provided that the option will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and will vest on the first anniversary of the grant date, provided that it will in any case be fully vested on the date of the Issuer's 2027 annual stockholder meeting.
OnKure Therapeutics, Inc.
Report date August 07, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2036-08-06 | Direct | 22,350 |
Reported balance
After 2026-08-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-07 · Grant · Acquired 22,350 · Balance 22,350 F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date.
SPRUCE BIOSCIENCES, INC.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.70 · Expires 2036-05-20 | Direct | 1,700 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 1,700 · Balance 1,700 F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest on the first anniversary of the Grant Date, provided that the Option will in any case be fully vested on the date of Company's 2027 annual stockholder meeting, subject to the Reporting Person's Continuous Service (as defined in the 2020 Equity Incentive Plan (the "Plan")) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Horizon Therapeutics Public Ltd Co
Report date October 06, 2023 · Filed October 06, 2023
Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 1
1 source rowRow 1 · 2023-10-06 · Disposition to issuer · Disposed 39,361 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Davy Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-10-06 · Disposition to issuer · Disposed 48,031 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Family Trust | 0 |
Reported balance
After 2023-10-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-10-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.53 · Expires 2025-05-05 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-06 · Disposition to issuer · Disposed 8,548 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.23 · Expires 2026-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-10-06 · Disposition to issuer · Disposed 23,092 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.12 · Expires 2027-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-10-06 · Disposition to issuer · Disposed 31,153 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.87 · Expires 2028-05-02 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-10-06 · Disposition to issuer · Disposed 32,161 · Balance 0 F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F2: The Option (as defined in footnote 3 to this Form 4) is fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2024-07-27 | Direct | 0 |
Reported balance
After 2023-10-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-10-06 · Disposition to issuer · Disposed 4,016 · Balance 0 F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F6: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration. F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
F2: The Option (as defined in footnote 3 to this Form 4) is fully vested.
F3: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.
F4: Each RSU (as defined in footnote 6 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.
F5: The Ordinary Shares subject to the RSUs vest on July 27, 2024.
F6: Reflects the disposition of Issuer's restricted stock unit awards (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was canceled and converted into the right to receive a cash amount equal to (i) the total number of Ordinary Shares subject to such RSU multiplied by (ii) the Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2018 Filed Jun 8, 2018 00:16 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-027784 · doc1.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,110 F1 · price: Restricted stock units granted on June 5, 2018. Price not applicable. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 15,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028367 · doc4.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,320 Underlying: Ordinary shares · 15,320 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantStock Option (Right to Buy) · Derivative | 32,161 | $0.00 Strike: $13.87 | $0.00 |
DisclosureSEC source: 0001209191-18-028367 · doc4.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,161 Underlying: Ordinary shares · 32,161 shares Expires 2028-05-02 F3 · derivative.exercise_date: The option vests in 12 equal monthly installments from the date of grant. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 14,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028367 · doc4.xml · derivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 14,054 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On May 3, 2017, the reporting person was granted 14,054 restricted stock units, vesting in full on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 3, 2017, the reporting person was granted 14,054 restricted stock units, vesting in full on the first anniversary of the grant date. Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 3,790 | $13.87 | $52,567.30 |
DisclosureSEC source: 0001209191-18-028367 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 35,712 Read SEC document |
| May 03, 2018 Filed May 7, 2018 17:05 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 14,054 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-028367 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 39,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 18, 2018 Filed Jan 22, 2018 23:00 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $27.00 | $0.00 |
DisclosureSEC source: 0001214659-18-000585 · marketforms-40824.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-01-17 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (right to buy) Common Stock · Derivative | 4,910 | $0.00 Strike: $89.60 | $0.00 |
DisclosureSEC source: 0001140361-17-024506 · doc1.xml · derivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2027-06-05 F2 · derivative.exercise_date: Option grant vests in full on June 6, 2018. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:25 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-024506 · doc1.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,810 F1 · price: Restricted stock units granted on June 6, 2017. Price not applicable. Read SEC document |
| May 17, 2017 Filed May 19, 2017 22:06 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.65 | $0.00 |
DisclosureSEC source: 0001190725-17-000128 · edgardoc.xml · derivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The shares subject to the Option vest and become exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| May 10, 2017 Filed May 10, 2017 19:22 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | PurchaseOrdinary Shares | 10,000 | $9.48 | $94,800.00 |
DisclosureSEC source: 0001209191-17-031417 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 25,448 Read SEC document |
| May 03, 2017 Filed May 4, 2017 17:59 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantRestricted Stock Units · Derivative | 14,054 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-030112 · doc4.xml · derivative · entry 5 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,054 Underlying: Ordinary shares · 14,054 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F1 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| May 03, 2017 Filed May 4, 2017 17:59 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | GrantStock Option (Right to Buy) · Derivative | 31,153 | $0.00 Strike: $15.12 | $0.00 |
DisclosureSEC source: 0001209191-17-030112 · doc4.xml · derivative · entry 4 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,153 Underlying: Ordinary shares · 31,153 shares Expires 2027-05-02 F3 · derivative.exercise_date: The option vests in 12 equal monthly installments from the date of grant. Read SEC document |
| May 03, 2017 Filed May 4, 2017 17:59 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 13,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-030112 · doc4.xml · derivative · entry 3 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary shares · 13,953 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: On May 3, 2016, the reporting person was granted 13,953 restricted stock units, vesting in full on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 3, 2016, the reporting person was granted 13,953 restricted stock units, vesting in full on the first anniversary of the grant date. Read SEC document |
| May 03, 2017 Filed May 4, 2017 17:59 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 3,763 | $15.12 | $56,896.56 |
DisclosureSEC source: 0001209191-17-030112 · doc4.xml · nonDerivative · entry 2 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 15,448 Read SEC document |
| May 03, 2017 Filed May 4, 2017 17:59 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 13,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-030112 · doc4.xml · nonDerivative · entry 1 GREY MICHAEL G · CIK 0001240122 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 19,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.